Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Ethics Resources and Policies
  • About the Journal
    • About CMR
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Clinical Microbiology Reviews
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Ethics Resources and Policies
  • About the Journal
    • About CMR
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Review

Strongyloides stercoralis in the Immunocompromised Population

Paul B. Keiser, Thomas B. Nutman
Paul B. Keiser
Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas B. Nutman
Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tnutman@niaid.nih.gov
DOI: 10.1128/CMR.17.1.208-217.2004
  • Article
  • Info & Metrics
  • PDF
Loading

SUMMARY

SUMMARY Strongyloides stercoralis is an intestinal nematode of humans that infects tens of millions of people worldwide. S. stercoralis is unique among intestinal nematodes in its ability to complete its life cycle within the host through an asexual autoinfective cycle, allowing the infection to persist in the host indefinitely. Under some conditions associated with immunocompromise, this autoinfective cycle can become amplified into a potentially fatal hyperinfection syndrome, characterized by increased numbers of infective filariform larvae in stool and sputum and clinical manifestations of the increased parasite burden and migration, such as gastrointestinal bleeding and respiratory distress. S. stercoralis hyperinfection is often accompanied by sepsis or meningitis with enteric organisms. Glucocorticoid treatment and human T-lymphotropic virus type 1 infection are the two conditions most specifically associated with triggering hyperinfection, but cases have been reported in association with hematologic malignancy, malnutrition, and AIDS. Anthelmintic agents such as ivermectin have been used successfully in treating the hyperinfection syndrome as well as for primary and secondary prevention of hyperinfection in patients whose exposure history and underlying condition put them at increased risk.

INTRODUCTION

Strongyloides stercoralis is an intestinal nematode of humans. It is estimated that tens of millions of persons are infected worldwide, although no precise estimate is available (42). Although most infected individuals are asymptomatic (43), S. stercoralis is capable of transforming into a fulminant fatal illness under certain conditions associated with a compromise of host immunity. Such conditions have commonly been summarized as “defects in cell-mediated immunity,” although the specific circumstances under which S. stercoralis hyperinfection develops are not always predictable.

Given the increasing numbers of immunocompromised individuals throughout the world, a closer examination of the conditions under which S. stercoralis infection becomes dangerous is warranted. Better approaches to identifying, screening, and treating those at risk will likely decrease the morbidity and mortality associated with S. stercoralis infection.

LIFE CYCLE

The S. stercoralis life cycle encompasses both free-living and parasitic stages. Adult female worms parasitizing the human small intestine lay eggs in the intestinal mucosa that hatch into rhabditiform larvae, which are shed in the stool. In the environment, under warm moist conditions that often characterize the tropical and subtropical areas where S. stercoralis is endemic, rhabditiform larvae can either molt into infective filariform larvae or develop through succeeding rhabditiform stages into free-living adults. Harsh environmental conditions are thought to be a stimulus towards development into parasitic stages. Sexual reproduction occurs exclusively in the free-living stage (80).

Humans are generally infected transcutaneously, although infection has also been experimentally induced by oral administration of water contaminated with filariform larvae (42). After dermal penetration, the filariform larvae, through undefined mechanisms, migrate to the small intestine. The most clinically relevant, though perhaps not the predominant (66), migration is the classic pulmonary route, in which organisms enter the bloodstream and are carried to the lungs, ascending the tracheobronchial tree to enter the gastrointestinal tract. Only female adults are detectable in humans, and subsequent reproduction occurs asexually (80).

Some rhabditiform larvae transform into invasive filariform larvae before being excreted. As such, they are capable of reinfecting the host by invading the intestinal wall or the perianal skin (42). This autoinfective cycle can occur at a low level throughout infection and allows subsequent generations to persist in the host indefinitely (80).

EPIDEMIOLOGY

Although S. stercoralis is often considered a disease of tropical and subtropical areas, endemic foci are also seen in temperate regions (5, 128). Low socioeconomic status (128), alcoholism (26), white race (24), and male gender (128) have been associated with higher prevalences of S. stercoralis stool positivity. Clusters of cases in institutionalized individuals with mental retardation (8, 93) suggest that nosocomial transmission can occur. Occupations that increase contact with soil contaminated with human waste, which may include farming (69, 98) and coal mining (127, 128) depending on local practices, increase the risk of infection. Swimming in or drinking contaminated water has not been proven to be a significant source of transmission, perhaps because larvae do not thrive when immersed in water (88). Different prevalences among ethnic groups (24, 128) may simply reflect behavioral or socioeconomic factors, but some have suggested that different skin types may be more or less resistant to larval penetration (128).

CLINICAL SYNDROMES

As the clinical syndromes of S. stercoralis encompass a spectrum and terms are used variably, it is necessary to set forth some definitions before proceeding further.

Acute StrongyloidiasisFrom experimental human infections, it is known that a local reaction at the site of larval entry can occur almost immediately and may last up to several weeks (31). Pulmonary symptoms such as a cough and tracheal irritation, mimicking bronchitis, occur as larvae migrate through the lungs several days later. Gastrointestinal symptoms (diarrhea, constipation, anorexia, abdominal pain) begin about 2 weeks after infection, with larvae detectable in the stool after 3 to 4 weeks. Experimental human infections on which this description is based were initiated with many hundreds of larvae and most likely overestimate the severity and perhaps the tempo of naturally acquired infections.

Chronic StrongyloidiasisChronic infection with S. stercoralis is most often asymptomatic (43). There are a number of signs and symptoms attributable to chronic strongyloidiasis that are unrelated to accelerated autoinfection. Chronic gastrointestinal manifestations, such as intermittent vomiting, diarrhea, constipation, and borborygmus, are common complaints. Pruritus ani and dermatologic manifestations such as urticaria and larva currens rashes are also common (89). Recurrent asthma (73, 109, 124) and nephrotic syndrome (133) have also been associated with chronic strongyloidiasis infection.

Complications such as intestinal obstruction (32), ileus (85), hemodynamically significant gastrointestinal bleeding, and acute worsening of chronic intestinal manifestations have occurred in the context of an increased larval burden. Even in the absence of pulmonary symptoms, such presentations could be considered a manifestation of hyperinfection when accompanied by large numbers of filariform larvae in the stool.

HyperinfectionHyperinfection describes the syndrome of accelerated autoinfection, generally — although not always (51, 120) — the result of an alteration in immune status. Parasitologically, the distinction between autoinfection and hyperinfection is quantitative and not strictly defined. Therefore, the diagnosis of hyperinfection syndrome implies the presence of signs and symptoms attributable to increased larval migration. Development or exacerbation of gastrointestinal and pulmonary symptoms is seen, and the detection of increased numbers of larvae in stool and/or sputum is the hallmark of hyperinfection. Larvae in nondisseminated hyperinfection are increased in numbers but confined to the organs normally involved in the pulmonary autoinfective cycle (i.e., gastrointestinal tract, peritoneum, lungs), although enteric bacteria, which can be carried by the filariform larvae or gain systemic access through intestinal ulcers, may affect any organ system.

Disseminated InfectionThe term disseminated infection is often used to refer to migration of larvae to organs beyond the range of the pulmonary autoinfective cycle. This does not necessarily imply a greater severity of disease. Extrapulmonary migration of larvae has been shown to occur routinely during the course of experimental chronic S. stercoralis infections in dogs (106) and has been reported to cause symptoms in humans without other manifestations of hyperinfection syndrome (57). Similarly, many cases of hyperinfection are fatal without larvae being detected outside the pulmonary autoinfective route.

As documenting disseminated infection may be more a matter of vigilance than a fundamental difference in disease mechanisms, the term hyperinfection will be used here to include cases with evidence of larval migration beyond the pulmonary autoinfective route.

HYPERINFECTION SYNDROME

General FeaturesThe clinical manifestations of S. stercoralis hyperinfection vary widely. The onset may be acute (121) or insidious (135). Fever and chills are not uniformly present and should prompt a search for an associated bacterial infection. Other constitutional symptoms include fatigue (61), weakness (14), and total body pain (13). Blood counts performed during hyperinfection may show eosinophilia but more often show a suppressed eosinophil count. Patients who have increased peripheral eosinophilia during hyperinfection appear to have a better prognosis (54).

Gastrointestinal ManifestationsGastrointestinal symptoms are most common but are nonspecific. Some case reports do not mention any gastrointestinal symptoms (97). Abdominal pain (12), often described as crampy (61) or bloating (20) in nature, watery diarrhea, constipation (61), anorexia, weight loss (61, 108), difficulty swallowing (136), sore throat (136), nausea (61), vomiting (61), and gastrointestinal bleeding (13), in any order or combination, are frequently reported. Ileus (76) and small bowel obstruction (83, 121) may result, with diffuse abdominal tenderness and hypoactive bowel sounds. Protein-losing enteropathy may give rise to acute or worsening hypoalbuminemia with peripheral edema (49) or ascites (61). Hypokalemia (53) and other electrolyte abnormalities may reflect these gastrointestinal disturbances.

Direct stool exam usually shows numerous rhabditiform and filariform larvae. Occasionally, adult worms (49) and eggs (3, 11) are also seen. Occult or gross blood is a common finding. Esophagitis and gastritis are reported, in addition to duodenitis, jejunitis, ileitis, colitis, including pseudomembranous colitis (53), and proctitis. Mucosal ulceration is most common in the small intestine, but can occur at any level from the esophagus (60) and stomach (135) to the rectum. Larvae may be seen in these ulcers on biopsy (38, 49, 135). Crypts are often distorted by the numerous larvae (135). Inflammatory infiltrates (76) and areas of necrosis (79, 136) in involved intestinal mucosa may (83) or may not (135) be present. The appendix may also be invaded by larvae (56, 108). Abdominal X-rays may show small bowel distension with air-fluid levels (12, 83). Mucosal edema (76, 79) and findings consistent with protein-losing enteropathy may also be demonstrated radiographically. Computed tomography scans can occasionally reveal intra-abdominal lymphadenopathy (121).

Cardiopulmonary ManifestationsPulmonary manifestations range from none at all to cough (84), wheezing (56, 136), a choking sensation (11), hoarseness (136), chest pain (11) (which may be pleuritic in nature (13), hemoptysis (in some cases massive) (61), palpitations, atrial fibrillation (39), dyspnea (84), and, rarely, respiratory collapse. Respiratory alkalosis is common (122). There is only one report of pneumothorax (73). If the diagnosis is not made and steroids are administered, symptoms may actually improve temporarily (113), although this experience is not universal (109).

Sputum may demonstrate filariform or rhabditiform larvae (15, 28, 37, 110) and even, occasionally, eggs (55). These findings suggest that filariform larvae develop into adults in the lungs and a new generation of rhabditiform larvae are produced locally (15). This hypothesis is supported by reports of adult parasites being expectorated posttreatment (72) and autopsy studies showing adult worms in lung tissue (11). Chest X-rays most frequently show bilateral (12) or focal (38) interstitial infiltrates. Lung tissues may show alveolar hemorrhage (11, 79). Petechial hemorrhage or hyperemia of the bronchial, tracheal (136), and laryngeal (11) mucosa has also been reported. Larvae seen on lung biopsy associated with inflammatory changes have been reported variably (13, 136).

Dermatologic ManifestationsPruritic linear streaks of the lower trunk, thighs, and buttocks (larva currens) frequently accompany hyperinfection (49). Petechial (39) and purpuric (97) rashes of the same areas, in which larvae have been demonstrated on skin biopsy, are also reported. Skin manifestations of vasculitis (44), the underlying disease, and/or associated gram-negative sepsis (121) with disseminated intravascular coagulation (79) may, of course, also be present during hyperinfection.

Central Nervous System ManifestationsMeningeal signs and symptoms (56) are the most common manifestation of central nervous system involvement. Hyponatremia may accompany meningitis (44, 53). In patients with meningitis, spinal fluid may show parameters of aseptic meningitis (i.e., pleocytosis, elevated protein, normal glucose, negative bacterial cultures) (108, 126) or demonstrate characteristics of a gram-negative bacterial infection. Larvae have been found in spinal fluid (28), meningeal vessels (11), the dura, and the epidural, subdural, and subarachnoid (79) spaces.

Spinal fluid cultures in hyperinfection have grown Escherichia coli (56, 97), Proteus mirabilis (12), Klebsiella pneumoniae (61), Enterococcus faecalis (56), and Streptococcus bovis (53, 63), among others. Eosinophilic meningitis has not been reported.

Other ManifestationsRare cases with liver dissemination may show an obstructive pattern in the liver enzymes, with elevations of the alkaline phosphatase and bilirubin (108) and, to a lesser extent, alanine aminotransferase and aspartate aminotransferase (59). Granulomata may be seen throughout the liver parenchyma, with periportal inflammation occurring around degenerating larvae (108).

Organs to which larvae have disseminated include skin (77, 79), mesenteric lymph nodes (11), gallbladder (11), liver (59), diaphragm (79), heart (12, 59, 77, 79), pancreas (75, 79), skeletal muscle (75, 77), kidneys, ovaries (79), and brain (75). Chronic inflammation or necrosis (79) frequently surrounds the larvae, but tissue reactions, even in the same patient, are also frequently absent (79, 119).

Hyperinfections are often complicated and, rarely, preceded (63) by infections caused by gut flora that gain access to extraintestinal sites, presumably through ulcers induced by the filariform larvae or by virtue of being carried on the surface or in the intestinal tract of the larvae themselves. Blood cultures from patients with hyperinfection have grown Escherichia coli (3, 97), Klebsiella pneumoniae (12), Proteus mirabilis (12, 121), Pseudomonas (61), Enterococcus faecalis (63), coagulase-negative staphylococci (101), Streptococcus bovis (63), and Streptococcus pneumoniae (12). Polymicrobial infections can also occur (63). In addition to enteric gram-negative rods spreading systemically in this fashion, patients on immunosuppressive regimens may also develop systemic Candida infections by presumably similar mechanisms (86, 94, 101).

IMMUNOCOMPROMISED CONDITIONS ASSOCIATED WITH S. STERCORALIS

Immunosuppressive Drug TherapyThe largest category of immunocompromise consists of those conditions that are pharmacologically induced to treat autoimmune, allergic, and inflammatory disorders as well as to prevent rejection of transplanted organs.

Glucocorticoids.Of all the immunosuppressive drugs prescribed, glucocorticoids are the most widely used and the most specifically associated with transforming chronic strongyloidiasis to hyperinfection.

Hyperinfection has resulted from high-dose steroids (113), low-dose steroids (135), locally injected steroids (130), high levels of endogenous adrenocorticotropin (21), and pharmacologically administered adrenocorticotropin (25). Hyperinfection has resulted from steroids administered for diseases that themselves could be considered as having intrinsic immunological abnormalities, i.e., lupus (94), lymphoma (94), rheumatoid arthritis (20), leprosy (94), and polymyositis (73) and also for nonsystemic inflammatory conditions such as corneal ulcer (108, 130) and Bell's palsy (25). Signs and symptoms have begun as early as 20 days after the onset of steroid therapy (25) and as late as several years (94) without an obvious additional immunocompromising condition supervening.

One likely explanation for the ability of glucocorticoids to induce hyperinfection is their acute suppression of eosinophilia (34) and lymphocyte activation. Some have suggested that glucocorticoids may also have a direct effect on the parasites themselves, accelerating the transformation of rhabditiform to invasive filariform larvae (35) or rejuvenating reproductively latent adult females (67). As intriguing as this hypothesis is, little experimental work to support it has been reported apart from the identification of S. stercoralis cDNA encoding nuclear hormone receptors (112).

Vinca alkaloids.Vincristine use has been associated with a number of cases of hyperinfection (54, 94, 118). Although most of these patients also received glucocorticoids, it has been proposed that vinca alkaloids exert a toxic effect on myenteric neurons, decreasing intestinal motility and increasing the amount of time that rhabdtiform larvae have to molt to invasive filariform larvae. The first reported case of hyperinfection complicating lymphoma was a 63-year-old man with Hodgkin's who received vinblastin sulfate (but not glucocorticoids) and developed fecal impaction shortly thereafter (95). Two reports describe S. stercoralis in patients who received vincristine but not glucocorticoids: one was a case of hyperinfection that occurred in a patient with high endogenous adrenocorticotropin levels due to small cell lung carcinoma (21); the other was a case not of hyperinfection but of eosinophilic gastroenteritis and recurrent eosinophilia (99). Therefore, evidence for vinca alkaloids themselves causing hyperinfection remains anecdotal.

Cyclosporine.Given its widespread use, the absence of an association of cyclosporine with S. stercoralis hyperinfection is striking. In fact, one notes a decline in case reports of hyperinfection occurring in renal transplant recipients after about 1990, when cyclosporine became a standard part of the posttransplant regimen. There is some experimental evidence that cyclosporin A may actually have an anthelmintic effect on S. stercoralis (105). The one case of S. stercoralis hyperinfection in a patient on cyclosporine occurred after the drug was withdrawn and cyclosporine levels were declining (87). Resuming cyclosporine therapy alone was not sufficient to cure the hyperinfection, but the patient did well once treated with thiabendazole.

Other immunosuppressive drugs.Numerous other drugs have contributed to immunosuppressive states associated with hyperinfection, including azathioprine (129), cyclophosphamide (29, 99, 118), antithymocyte globulin (74, 131), anti-CD3 (87), chlorambucil (94), 6-mercaptopurine (94), methotrexate (99, 118), bleomycin (118), adriamycin (99), doxorubicin (104, 118), daunorubicin (23), ifosfamide (118), melphalan (104), carmustine (104), VP16 (96, 118), and mitoxantrone (118), as well as total body irradiation (95). In all of these cases, glucocorticoids were administered contemporaneously. Attributing hyperinfection to any of these other drugs alone is therefore difficult.

Hematologic MalignanciesGlucocorticoids are employed in the treatment of many hematologic malignancies, but there are case reports of S. stercoralis hyperinfection developing in such patients prior to therapy (1, 132). In one case of small intestinal lymphoma, in which S. stercoralis larvae were seen in large numbers in the lymphomatous tissue itself; the authors suggest that chronic parasite-induced inflammation may have contributed to the development of the lymphoma in the first place (16).

Kidney TransplantsThe majority of cases of hyperinfection that have occurred following organ transplant have occurred following renal transplant, and most of these cases seem to have been precipitated by increased glucocorticoid doses in response to rejection (9, 18, 27, 50, 58, 74, 87, 116, 125, 129, 131). The lack of reported cases following heart, lung, and liver transplants may simply reflect the fewer patients from Strongyloides-endemic areas receiving these transplants. As mentioned above, the number of reported cases of hyperinfection following renal transplant has declined with the use of cyclosporine.

One interesting feature of S. stercoralis in renal transplants is the number of cases in which invasive larvae have been found in the urine of these patients (29, 50, 74). One might speculate that a kidney in the peritoneal cavity is more likely to be encountered and invaded by migrating larvae. Larvae have been found in the urine of non-renally transplanted patients, as well (10, 14), so a peritoneal location is not a prerequisite for renal dissemination. In fact, some have suggested that the kidneys themselves may be capable of transmitting S. stercoralis from donor to recipient (50).

Bone Marrow TransplantsRelatively few cases of S. stercoralis hyperinfection following bone marrow transplant have been reported in the English literature. One intriguing case documented the presence of S. stercoralis eggs containing viable larvae on a urethral smear (114). A suggestion raised by the authors is that normal hatching of larvae from the eggs was prevented by drugs used for the bone marrow transplant (busulfan and cyclophosphamide), although no in vitro evidence has been presented to explore this possibility further. If some immunosuppressive drugs do indeed prevent egg hatching and therefore decrease the number of filariform larvae exposed to the intestinal mucosa, one would expect hyperinfection to be rare in individuals in whom pharmacologic immunosuppression is induced by those drugs.

HTLV-1 InfectionInfection with human T-lymphotropic virus type 1 (HTLV-1) is associated with increased prevalence of S. stercoralis infection (with direct stool studies as the criterion) (45), greater refractoriness to conventional treatment (102), and the hyperinfection syndrome (40).

S. stercoralis also appears to influence the natural course of HTLV-1 infection. HTLV-1-infected individuals with adult T-cell leukemia who are coinfected with S. stercoralis are significantly younger than patients with adult T-cell leukemia but without S. stercoralis infection, suggesting that coinfections shortens the period of latency prior to leukemogenesis (90). One reason for this may be that HTLV-1- and Strongyloides-coinfected individuals have an expanded population of HTLV-1-infected CD4+ CD25+ T cells and higher levels of circulating proviral DNA (103), which is associated with accelerated disease course.

From the parasite perspective, HTLV-1-infected hosts appear to be more tolerant because of a virally induced Th1 bias to their immune system. Peripheral blood mononuclear cells from HTLV-1-infected patients produce more gamma interferon at baseline (81), and these patients appear to make less polyclonal (81) and parasite-specific (92) immunoglobulin E.

HIV InfectionAlthough S. stercoralis hyperinfection was once considered an opportunistic AIDS-defining illness (134), the relative rarity of such case reports despite the vast numbers of people who must be coinfected is striking (64). In all, there are fewer than 30 cases of hyperinfection occurring in human immunodeficiency virus (HIV)-infected patients in the literature. A number of these patients had previously received steroids, either as adjunctive treatment for Pneumocystis carinii pneumonia (15, 65, 100) or as part of a chemotherapeutic regimen for non-Hodgkin's lymphoma (28). HTLV-1 infection is generally not commented on in these case reports. Therefore, a link between the two conditions is not solid.

The number of cases of hyperinfection in AIDS patients that have occurred within a few weeks of treating chronic intestinal infection (38, 44, 59, 65, 123) is interesting. Whether anthelmintic therapy actually induces parasite migration, as occurs in filarial infections (30, 117), and is thereby the initiating event in hyperinfection is a matter for speculation. This “posttreatment hyperinfection” has also been observed in renal transplant recipients (108) in whom S. stercoralis infection was treated both before and after transplant. While these cases undoubtedly represent a tiny fraction of AIDS patients who have received anthelmintic treatment for positive stool exams, it does challenge the notion that screening HIV-positive individuals for S. stercoralis and treating coinfected individuals with conventional doses of anthelmintics will prevent hyperinfection (65).

HypogammaglobulinemiaCases of S. stercoralis hyperinfection have been reported with hypogammaglobulinemia (7, 110). Both of the patients in these reports were particularly refractory to prolonged anthelmintic therapy. The implication that antibody is important in controlling S. stercoralis infection is also supported by experimental animal models (48).

Malnutrition and Associated ConditionsLung cancer has been associated with hyperinfection, both before (55, 96) and after (21, 96) administration of immunosuppressive chemotherapy. Hyperinfections complicating kala-azar (78) and other conditions of protein-energy malnutrition with wasting have also been reported. Whether these conditions predispose to hyperinfection through depressed immunity directly or through metabolic perturbations of endogenous cortisol were not investigated. Certainly malnutrition and the poor hygienic conditions associated with S. stercoralis infection frequently coexist, but, of course, these are the very areas where resources for studying the association are most limited.

DIAGNOSIS OF S. STERCORALIS INFECTION IN THE IMMUNOCOMPROMISED PATIENT

Parasitologic diagnosis of S. stercoralis hyperinfection is relatively straightforward, given the high numbers of larvae that exist in stool and, usually, sputum. Unexpected diagnoses have even been made from ascitic fluid (61) and blood smears (133). The real challenge is screening patients prior to and during immunosuppressive therapy.

Screening At-Risk IndividualsAny individual with risk factors for acquiring S. stercoralis infection who is diagnosed with HTLV-1 or who is to undergo steroid therapy should be screened. Hyperinfection has occurred in patients on doses as low as 1 mg of dexamethasone daily for 8 weeks (121). Because of the longevity of the parasitic infection, even remote histories of travel, i.e., veterans of wars in the South Pacific (89) or southeast Asia (36) or residence in places where the disease was considered endemic decades ago, i.e., rural Appalachia (5), should prompt screening. In addition, peripheral eosinophilia or symptoms consistent with chronic strongyloidiasis should alert the clinician to the possibility of underlying S. stercoralis, although these are neither sensitive nor specific indicators of infection.

Diagnosis of HyperinfectionRelying on stool studies alone for screening is inadequate, as evidenced by reports of hyperinfection developing in persons with negative screening stool exams. In chronic asymptomatic S. stercoralis infection, adult parasites may produce only 10 to 15 eggs per day (35). A single stool exam is said to be about 50% sensitive for making the diagnosis of S. stercoralis infection in someone with symptomatic chronic disease (111). In the asymptomatic individual, stool exams are probably even less sensitive.

The Baermann and formalin-ethyl acetate concentration techniques have been widely used to improve the sensitivity of stool exams. The Harada-Mori filter paper culture does not appear to be as successful for Strongyloides as it has been for hookworm (17). The blood agar plate culture method, in which the serpiginous tracks of bacterial growth along the paths of motile larvae become apparent after 1 or 2 days of incubation at room temperature, is a preferred method because of its high sensitivity and ease of implementation in standard microbiology laboratories (17, 111). Methods to sample duodenal fluid are more invasive and therefore less desirable.

Skin testing for immediate hypersensitivity with parasite extracts has been tried experimentally, but this is not widely available (82). Coinfection with HTLV-1 has been shown to decrease the sensitivity of the skin test (81, 92), and it can be presumed that other immunocompromising conditions and antihistamine therapies would have a similar effect.

Serologic testing is now widely available and is sensitive although not specific. Infections with filariae or Ascaris spp. can lead to false-positives. Furthermore, the sensitivity of serologic tests may be decreased in HTLV-1 infection (92) and in hematologic malignancies (107). A single test does not reliably distinguish past from current infection, but given the persistent nature of S. stercoralis infection and the possibility that curative treatment may not completely eradicate every last organism, a positive serology test in a patient with a compatible clinical history preparing to undergo steroid therapy may be sufficient grounds for empirical treatment.

TREATMENT OF S. STERCORALIS IN THE IMMUNOCOMPROMISED PATIENT

As different immunocompromised states are associated with different degrees of refractoriness to therapy, the therapeutic regimen must be customized. Patients with hypogammaglobulinemia, for example, have been refractory to multiyear courses of thiabendazole (110) and ivermectin (4), while numerous cases of steroid-induced and AIDS-associated (123) hyperinfection have resolved with more conventional doses.

Anthelmintic Drug Treatment OptionsClinical trials assessing drug treatment of S. stercoralis infection have, for the most part, focused on patients with chronic strongyloidiasis, not hyperinfection. The criteria for success in these studies are improvement in symptoms and negative stool exams; however, it presumably takes only one viable worm to initiate hyperinfection under the right circumstances. The goal of treatment to prevent hyperinfection, therefore, is total eradication of the parasite, not just symptomatic improvement. The regimens necessary to accomplish this are not clearly defined.

Azole drugs.Thiabendazole was first introduced in 1963 and for many years was the treatment of choice for S. stercoralis infection. At a dose of 25 mg/kg twice a day for 3 days, its efficacy at clearing stool and improving symptoms in patients with chronic strongyloidiasis has ranged from 67% (41) to 81% (36). Side effects with thiabendazole occur in up to 95% of patients (33), with the majority reporting nausea and many complaining of foul-smelling urine, neuropsychiatric effects, malaise, or dizziness (41). Thiabendazole administered rectally was used successfully in treating a patient with S. stercoralis hyperinfection and bowel obstruction (6).

Mebendazole has been used successfully to treat a number of patients with S. stercoralis hyperinfection (115). It is poorly absorbed, however, and therefore decreased accessibility to migrating larvae may have played a role in cases where mebendazole was unsuccessful (19, 49).

Albendazole at 400 mg orally twice a day for 3 days has been shown to clear stool of S. stercoralis larvae in 38% to 45% of patently infected individuals (22, 70) and to normalize serologies in 75% of chronically infected individuals in whom larvae were not detectable, with few side effects reported (2). Albendazole has been used successfully in hyperinfection syndrome (78) and remains a viable treatment alternative to ivermectin (see below).

Ivermectin.In a small comparative study with thiabendazole, ivermectin given on 1 or 2 days cleared larvae from the stool at a rate comparable to that of thiabendazole (33). Ivermectin, however, was much better tolerated and has become the treatment of choice. Compared with albendazole, ivermectin has shown better rates of larval clearance from stool with a similarly favorable side effect profile (22, 70). It has been used successfully in hyperinfection (123), including cases that did not respond adequately to thiabendazole (84).

Clinical Scenarios

Treatment of hyperinfection.Optimal anthelmintic activity for both azoles and ivermectin requires an intact immune system, as evidenced by refractory infections in patients with various immunodeficiencies (60, 83, 110). Therefore, treatment should continue until the clinical syndrome resolves and larvae are no longer detectable. The most practical detection methods only sample the intestinal compartment. Assuming that the autoinfective cycle requires at least 2 weeks, treatment and screening should continue until fecal cultures have been negative for at least this long. Patients who have had positive sputum or urine samples should continue to be examined as well. Decreasing the steroid dose has been advocated, but this may (20) or may not (122) be beneficial. Surgical blind loops may sequester organisms and require invasive methods to deliver anthelmintics at effective concentrations (108).

Coincident infection with enteric organisms is very common. Empirical or culture-driven antibacterial (or antifungal) coverage is warranted in those with evidence of additional infecting organisms. Adult respiratory distress syndrome may also occur during the course of hyperinfection (77, 122), often requiring mechanical ventilation.

It should be borne in mind that hospitalized patients with hyperinfection are infectious and should be placed on contact isolation. Use of gloves, masks, and aprons and diligent hand washing are effective measures that will prevent spread to health care workers (68) and other patients. Screening family members, particularly spouses (62, 88) and those with shared risk factors (105), should be considered in some circumstances, because person-to-person transmission is hypothetically possible.

Primary prevention of hyperinfection.Individuals initiating steroid therapy who have positive serologic tests and an exposure history but no history of S. stercoralis hyperinfection should have baseline stool examinations. Regardless of the results, it could be argued that they should receive a course of treatment (ivermectin, 200 μg/kg/day for 2 days, repeat after 2 weeks). Subsequent decisions about screening and prophylactic ivermectin must be individualized, but at the very least, a low threshold for performing stool exams should be maintained.

Patients with HTLV-1 who have positive results on serologic testing or stool examinations should receive a course of treatment and be followed for decreasing titers and/or clearance of larvae from stool culture.

Persons residing in strongyloidiasis-endemic areas or in high-risk occupations need to be educated about modes of parasite transmission to avoid recurrent infection.

Secondary prevention of hyperinfection.Given the reported cases of hyperinfection that have occurred following treatment and apparent clearance of Strongyloides (27, 29, 125), some clinicians have continued anthelmintics in individuals with a history of hyperinfection for extended periods. Two-day courses of thiabendazole given every two weeks have been successful (108), although there are reports of patients that continued to shed larvae (60) and developed symptomatic disease (45) on this regimen. If multiple courses of anthelmintic treatment are to be given for an extended period, ivermectin is better tolerated and should be the drug of choice. If secondary prophylaxis is not pursued, patients with a history of S. stercoralis hyperinfection should at the very least be screened periodically as long as their underlying predisposing condition persists.

CONCLUSIONS

Our understanding of S. stercoralis infections in normal and immunocompromised hosts continues to evolve. Relatively recently, it was thought that any defect in cellular immunity could tip the equilibrium of chronic strongyloidiasis toward hyperinfection. Although various immunocompromising conditions have been associated with hyperinfection, steroids and HTLV-1 infection are the most consistent. What these two conditions have in common is an effect on that arm of the immune system that controls many helminthic infections, the so-called Th2 response. This represents a complex interaction of antibody, particularly immunoglobulin E and immunoglobulin G4, T-cell-derived cytokines (notably interleukin-4 and -5), and peripheral and tissue eosinophils. While steroid treatment acutely suppresses eosinophilia and T-cell activation, HTLV-1 infection increases basal gamma interferon production by T cells and reduces immunoglobulin E levels (91). The importance of Th2 cytokines in controlling S. stercoralis infection has also been demonstrated in animal models (47, 48). The altered cytokine milieu in cases of hematologic malignancies may also explain how these conditions could result in S. stercoralis hyperinfection.

Although AIDS and malnutrition have both been associated with hyperinfection, the number of reported cases is much less than the overlapping endemicities of these conditions would predict. AIDS does not specifically impair Th2 immunity, and individuals in malnourished communities often have other chronic infections that maintain a Th2 bias. In fact, relatively few cases of Strongyloides hyperinfection have been associated with other concomitant helminth infections (38, 78), although the area of endemicity and modes of acquisition overlap considerably. Animal models support the notion that chronic infection with other helminths improves host resistance to S. stercoralis (71).

Practical issues regarding diagnosis, treatment, and primary and secondary prophylaxis of S. stercoralis hyperinfection are far from resolved, but the development of sensitive screening serologic tests and well-tolerated anthelmintic drugs represent significant advances in the past decade. Clinicians with an awareness of the possibility of hyperinfection are better equipped to diagnose, treat, or prevent altogether the fatal consequences of this lethal nematode.

ACKNOWLEDGMENTS

We gratefully acknowledge the editorial assistance of Brenda Rae Marshall.

  • Copyright © 2004 American Society for Microbiology

REFERENCES

  1. 1.↵
    Adam, M., O. Morgan, C. Persaud, and W. N. Gibbs. 1973. Hyperinfection syndrome with Strongyloides stercoralis in malignant lymphoma. Br. Med. J.1:264-266.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Archibald, L. K., N. J. Beeching, G. V. Gill, J. W. Bailey, and D. R. Bell. 1993. Albendazole is effective treatment for chronic strongyloidiasis. Q. J. Med.86:191-195.
    OpenUrlPubMed
  3. 3.↵
    Armignacco, O., A. Capecchi, P. De Mori, and L. R. Grillo. 1989. Strongyloides stercoralis hyperinfection and the acquired immunodeficiency syndrome. Am. J. Med.86:258.
    OpenUrlPubMedWeb of Science
  4. 4.↵
    Ashraf, M., C. L. Gue, and L. M. Baddour. 1996. Case report: strongyloidiasis refractory to treatment with ivermectin. Am. J. Med. Sci.311:178-179.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Berk, S. L., A. Verghese, S. Alvarez, K. Hall, and B. Smith. 1987. Clinical and epidemiologic features of strongyloidiasis. A prospective study in rural Tennessee. Arch. Intern. Med.147:1257-1261.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Boken, D. J., P. A. Leoni, and L. C. Preheim. 1993. Treatment of Strongyloides stercoralis hyperinfection syndrome with thiabendazole administered per rectum. Clin. Infect. Dis.16:123-126.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    Brandt de Oliveira, R., J. C. Voltarelli, and U. G. Meneghelli. 1981. Severe strongyloidiasis associated with hypogammaglobulinaemia. Parasite Immunol.3:165-169.
    OpenUrlPubMedWeb of Science
  8. 8.↵
    Braun, T. I., T. Fekete, and A. Lynch. 1988. Strongyloidiasis in an institution for mentally retarded adults. Arch. Intern. Med.148:634-636.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Briner, J., J. Eckert, D. Frei, F. Largiader, U. Binswanger, and A. Blumberg. 1978. Strongyloidiasis following kidney transplantation. Schweiz. Med. Wochenschr.108:1632-1637. (In German.)
    OpenUrlPubMed
  10. 10.↵
    Buss, D. H. 1971. Strongyloides stercoralis infection complicating granulocytic leukemia. N.C. Med. J.32:269-274.
    OpenUrl
  11. 11.↵
    Cahill, K. M., and M. Shevchuk. 1996. Fulminant, systemic strongyloidiasis in AIDS. Ann. Trop. Med. Parasitol.90:313-318.
    OpenUrlPubMed
  12. 12.↵
    Celedon, J. C., U. Mathur-Wagh, J. Fox, R. Garcia, and P. M. Wiest. 1994. Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature. Medicine (Baltimore)73:256-263.
    OpenUrlPubMed
  13. 13.↵
    Chaudhuri, B., S. Nanos, J. N. Soco, and E. A. McGrew. 1980. Disseminated Strongyloides stercoralis infestation detected by sputum cytology. Acta Cytol.24:360-362.
    OpenUrlPubMed
  14. 14.↵
    Chu, E., W. L. Whitlock, and R. A. Dietrich. 1990. Pulmonary hyperinfection syndrome with Strongyloides stercoralis. Chest97:1475-1477.
    OpenUrlCrossRefPubMed
  15. 15.↵
    Cirioni, O., A. Giacometti, F. Burzacchini, M. Balducci, and G. Scalise. 1996. Strongyloides stercoralis first-stage larvae in the lungs of a patient with AIDS: primary localization or a noninvasive form of dissemination? Clin. Infect. Dis.22:737.
    OpenUrlCrossRefPubMed
  16. 16.↵
    Cohen, J., and C. J. Spry. 1979. Strongyloides stercoralis infection and small intestinal lymphoma. Parasite Immunol.1:167-178.
    OpenUrlPubMed
  17. 17.↵
    Conway, D. J., J. F. Lindo, R. D. Robinson, and D. A. Bundy. 1995. Towards effective control of Strongyloides stercoralis. Parasitol. Today.11:420-424.
    OpenUrlCrossRefWeb of Science
  18. 18.↵
    Cook, G. A., H. Rodriguez, H. Silva, B. Rodriguez-Iturbe, and H. Bohorquez de Rodriguez. 1987. Adult respiratory distress secondary to strongyloidiasis. Chest92:1115-1116.
    OpenUrlCrossRefPubMed
  19. 19.↵
    Coovadia, Y. M., M. C. Rajput, and R. H. Bhana. 1993. Disseminated strongyloidiasis in a diabetic patient. Trop. Geogr. Med.45:179-180.
    OpenUrlPubMed
  20. 20.↵
    Coulter, C., D. G. Walker, M. Gunsberg, I. G. Brown, J. F. Bligh, and P. Prociv. 1992. Successful treatment of disseminated strongyloidiasis. Med. J. Aust.157:331-332.
    OpenUrlPubMed
  21. 21.↵
    Cummins, R. O., P. M. Suratt, and D. A. Horwitz. 1978. Disseminated Strongyloides stercoralis infection. Association with ectopic adrenocorticotropin syndrome and depressed cell-mediated immunity. Arch. Intern. Med.138:1005-1006.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Datry, A., I. Hilmarsdottir, R. Mayorga-Sagastume, M. Lyagoubi, P. Gaxotte, S. Biligui, J. Chodakewitz, D. Neu, M. Danis, and M. Bentilini. 1994. Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans. R. Soc. Trop. Med. Hyg.88:344-345.
    OpenUrlCrossRefPubMed
  23. 23.↵
    Daubenton, J. D., H. A. Buys, and P. S. Hartley. 1998. Disseminated strongyloidiasis in a child with lymphoblastic lymphoma. J. Pediatr. Hematol. Oncol.20:260-263.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    Davidson, R. A., R. H. Fletcher, and L. E. Chapman. 1984. Risk factors for strongyloidiasis. A case-control study. Arch. Intern. Med.144:321-324.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    Debussche, X., M. Toublanc, J. P. Camillieri, and R. Assan. 1988. Overwhelming strongyloidiasis in a diabetic patient following adrenocorticotropin treatment and keto-acidosis. Diabetes Metab.14:294-298.
    OpenUrlWeb of Science
  26. 26.↵
    de Oliveira, L. C., C. T. Ribeiro, Dde. M. Mendes, T. C. Oliveira, and J. M. Costa-Cruz. 2002. Frequency of Strongyloides stercoralis infection in alcoholics. Mem. Inst. Oswaldo Cruz97:119-121.
    OpenUrlPubMedWeb of Science
  27. 27.↵
    DeVault, G. A. Jr., J. W. King, M. S. Rohr, M. D. Landreneua, S. T. Brown III, and J. C. McDonald. 1990. Opportunistic infections with Strongyloides stercoralis in renal transplantation. Rev. Infect. Dis.12:653-671.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    Dutcher, J. P., S. L. Marcus, H. B. Tanowitz, M. Wittner, J. Z. Fuks, and P. H. Wiernik. 1990. Disseminated strongyloidiasis with central nervous system involvement diagnosed antemortem in a patient with acquired immunodeficiency syndrome and Burkitts lymphoma. Cancer66:2417-2420.
    OpenUrlCrossRefPubMed
  29. 29.↵
    Fowler, C. G., I. Lindsay, J. Levin, P. Sweny, O. N. Fernando, and J. F. Moorhead. 1982. Recurrent hyperinfestation with Strongyloides stercoralis in a renal allograft recipient. Br. Med. J. (Clin. Res. Ed.)285:1394.
    OpenUrlPubMed
  30. 30.↵
    Francis, H., K. Awadzi, and E. A. Ottesen. 1985. The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity. Am. J. Trop. Med. Hyg.34:529-536.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    Freedman, D. O. 1991. Experimental infection of human subject with Strongyloides species. Rev. Infect. Dis.13:1221-1226.
    OpenUrlCrossRefPubMed
  32. 32.↵
    Friedenberg, F., H. Wongpraparut, R. A. Fischer, J. Gubernick, N. Zaeri, G. Eiger, and Z. Ozden. 1999. Duodenal obstruction caused by Strongyloides stercoralis enteritis in an HTLV-1-infected host. Dig. Dis. Sci.44:1184-1188.
    OpenUrlCrossRefPubMed
  33. 33.↵
    Gann, P. H., F. A. Neva, and A. A. Gam. 1994. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J. Infect. Dis.169:1076-1079.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    Genta, R. M. 1989. Immunology, p. 133-153. In D. I. Grove (ed.), Strongyloidiasis: a major roundworm infection of man. Taylor & Francis, Philadelphia, Pa.
  35. 35.↵
    Genta, R. M. 1992. Dysregulation of strongyloidiasis: a new hypothesis. Clin. Microbiol. Rev.5:345-355.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    Gill, G. V., and D. R. Bell. 1979. Strongyloides stercoralis infection in former Far East prisoners of war. Br. Med. J.2:572-574.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    Gocek, L. A., P. J. Siekkinen, and M. R. Lankerani. 1985. Unsuspected Strongyloides coexisting with adenocarcinoma of the lung. Acta Cytol.29:628-631.
    OpenUrlPubMed
  38. 38.↵
    Gompels, M. M., J. Todd, B. S. Peters, J. Main, and A. J. Pinching. 1991. Disseminated strongyloidiasis in AIDS: uncommon but important. AIDS5:329-332.
    OpenUrlPubMedWeb of Science
  39. 39.↵
    Gordon, S. M., A. A. Gal, A. R. Solomon, and J. A. Bryan. 1994. Disseminated strongyloidiasis with cutaneous manifestations in an immunocompromised host. J. Am. Acad. Dermatol.31:255-259.
    OpenUrlPubMedWeb of Science
  40. 40.↵
    Gotuzzo, E., A. Terashima, H. Alvarez, R. Tello, R. Infante, D. M. Watts, and D. O. Freedman. 1999. Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru. Am. J. Trop. Med. Hyg.60:146-149.
    OpenUrlAbstract
  41. 41.↵
    Grove, D. I. 1982. Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness. Trans. R. Soc. Trop. Med. Hyg.76:114-118.
    OpenUrlCrossRefPubMed
  42. 42.↵
    Grove, D. I. 1989. Historical introduction, p. 1-9. In D. I. Grove (ed.), Strongyloidiasis: a major roundworm infection of man. Taylor & Francis, Philadelphia, Pa.
  43. 43.↵
    Grove, D. I. 1989. Clinical manifestations, p. 155-173. In D. I. Grove (ed.), Strongyloidiasis: a major roundworm infection of man. Taylor & Francis, Philadelphia, Pa.
  44. 44.↵
    Harcourt-Webster, J. N., F. Scaravilli, and A. H. Darwish. 1991. Strongyloides stercoralis hyperinfection in an HIV positive patient. J. Clin. Pathol.44:346-348.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    Hayashi, J., Y. Kishihara, E. Yoshimura, N. Furusyo, K. Yamaji, Y. Kawakami, H. Murakami, and S. Kashiwagi. 1997. Correlation between human T cell lymphotropic virus type-1 and Strongyloides stercoralis infections and serum immunoglobulin E responses in residents of Okinawa, Japan. Am. J. Trop. Med. Hyg.56:71-75.
    OpenUrlAbstract/FREE Full Text
  46. 46.
    Heath, T., S. Riminton, R. Garsia, and C. MacLeod. 1996. Systemic strongyloidiasis complicating HIV: a promising response to ivermectin. Int. J. STD AIDS7:294-296.
    OpenUrlCrossRefPubMed
  47. 47.↵
    Herbert, D. R., J. J. Lee, N. A. Lee, T. J. Nolan, G. A. Schad, and D. Abraham. 2000. Role of IL-5 in innate and adaptive immunity to larval Strongyloides stercoralis in mice. J. Immunol.165:4544-4551.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    Herbert, D. R., T. J. Nolan, G. A. Schad, and D. Abraham. 2002. The role of B cells in immunity against larval Strongyloides stercoralis in mice. Parasite Immunol.24:95-101.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    Ho, P. L., W. K. Luk, A. C. Chan, and K. Y. Yuen. 1997. Two cases of fatal strongyloidiasis in Hong Kong. Pathology29:324-326.
    OpenUrlCrossRefPubMed
  50. 50.↵
    Hoy, W. E., N. J. Roberts Jr., M. F. Bryson, C. Bowles, J. C. Lee, A. J. Rivero, and A. L. Ritterson. 1981. Transmission of strongyloidiasis by kidney transplant? Disseminated strongyloidiasis in both recipients of kidney allografts from a single cadaver donor. JAMA246:1937-1939.
    OpenUrlCrossRefPubMed
  51. 51.↵
    Husni, R. N., S. M. Gordon, D. L. Longworth, and K. A. Adal. 1996. Disseminated Strongyloides stercoralis infection in an immunocompetent patient. Clin. Infect. Dis.23:663.
    OpenUrlCrossRefPubMed
  52. 52.
    Igra-Siegman, Y., R. Kapila, P. Sen, Z. C. Kaminski, and D. B. Louria. 1981. Syndrome of hyperinfection with Strongyloides stercoralis. Rev. Infect. Dis.3:397-407.
    OpenUrlCrossRefPubMedWeb of Science
  53. 53.↵
    Jain, A. K., S. K. Agarwal, and W. el-Sadr. 1994. Streptococcus bovis bacteremia and meningitis associated with Strongyloides stercoralis colitis in a patient infected with human immunodeficiency virus. Clin. Infect. Dis.18:253-254.
    OpenUrlCrossRefPubMedWeb of Science
  54. 54.↵
    Jamil, S. A., and E. Hilton. 1992. The Strongyloides hyperinfection syndrome. N. Y. St. J. Med.92:67-68.
    OpenUrlPubMed
  55. 55.↵
    Kennedy, S., R. M. Campbell, J. E. Lawrence, G. M. Nichol, and D. M. Rao. 1989. A case of severe Strongyloides stercoralis infection with jejunal perforation in an Australian ex-prisoner-of-war. Med. J. Aust.150:92-93.
    OpenUrlPubMedWeb of Science
  56. 56.↵
    Kramer, M. R., P. A. Gregg, M. Goldstein, R. Llamas, and B. P. Krieger. 1990. Disseminated strongyloidiasis in AIDS and non-AIDS immunocompromised hosts: diagnosis by sputum and bronchoalveolar lavage. South. Med. J.83:1226-1229.
    OpenUrlPubMed
  57. 57.↵
    Lai, C. P., Y. H. Hsu, J. H. Wang, and C. M. Lin. 2002. Strongyloides stercoralis infection with bloody pericardial effusion in a non-immunosuppressed patient. Circ. J.66:613-614.
    OpenUrlCrossRefPubMedWeb of Science
  58. 58.↵
    Leapman, S. B., J. B. Rosenberg, R. S. Filo, and E. J. Smith. 1980. Strongyloides stercoralis in chronic renal failure: safe therapy with thiabendazole. South. Med. J.73:1400-1402.
    OpenUrlPubMed
  59. 59.↵
    Lessnau, K. D., S. Can, and W. Talavera. 1993. Disseminated Strongyloides stercoralis in human immunodeficiency virus-infected patients. Treatment failure and a review of the literature. Chest104:119-122.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    Levi, G. C., E. G. Kallas, and K. Ramos Moreira Leite. 1997. Disseminated Strongyloides stercoralis infection in an AIDS patient: the role of suppressive therapy. Braz. J. Infect. Dis.1:48-51.
    OpenUrlPubMed
  61. 61.↵
    Liepman, M. 1975. Disseminated Strongyloides stercoralis. A complication of immunosuppression. JAMA231:387-388.
    OpenUrlCrossRefPubMedWeb of Science
  62. 62.↵
    Lindo, J. F., R. D. Robinson, S. I. Terry, P. Vogel, A. A. Gam, F. A. Neva, and D. A. Bundy. 1995. Age-prevalence and household clustering of Strongyloides stercoralis infection in Jamaica. Parasitology110:97-102.
    OpenUrlCrossRefPubMedWeb of Science
  63. 63.↵
    Link, K., and R. Orenstein. 1999. Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. South. Med. J.92:728-731.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    Lucas, S. B. 1990. Missing infections in AIDS. Trans. R. Soc. Trop. Med. Hyg.84(Suppl. 1):34-38.
    OpenUrlCrossRefPubMed
  65. 65.↵
    Maayan, S., G. P. Wormser, J. Widerhorn, E. R. Sy, Y. H. Kim, and J. A. Ernst. 1987. Strongyloides stercoralis hyperinfection in a patient with the acquired immune deficiency syndrome. Am. J. Med.83:945-948.
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.↵
    Mansfield, L. S., A. Alavi, J. A. Wortman, and G. A. Schad. 1995. Gamma camera scintigraphy for direct visualization of larval migration in Strongyloides stercoralis-infected dogs. Am. J. Trop. Med. Hyg.52:236-240.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    Mansfield, L. S., S. Niamatali, V. Bhopale, S. Volk, G. Smith, J. B. Lok, R. M. Genta, and G. A. Schad. 1996. Strongyloides stercoralis: maintenance of exceedingly chronic infections. Am. J. Trop. Med. Hyg.55:617-624.
    OpenUrlAbstract/FREE Full Text
  68. 68.↵
    Maraha, B., A. G. Buiting, C. Hol, R. Pelgrom, C. Blotkamp, and A. M. Polderman. 2001. The risk of Strongyloides stercoralis transmission from patients with disseminated strongyloidiasis to the medical staff. J. Hosp. Infect.49:222-224.
    OpenUrlCrossRefPubMed
  69. 69.↵
    Marnell, F., A. Guillet, and C. Holland. 1992. A survey of the intestinal helminths of refugees in Juba, Sudan. Ann. Trop. Med. Parasitol.86:387-393.
    OpenUrlPubMed
  70. 70.↵
    Marti, H., H. J. Haji, L. Savioli, H. M. Chwaya, A. F. Mgeni, J. S. Ameir, and C. Hatz. 1996. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am. J. Trop. Med. Hyg.55:477-481.
    OpenUrlAbstract/FREE Full Text
  71. 71.↵
    Maruyama, H., Y. Osada, A. Yoshida, M. Gutakuchi, H. Kawaguchi, R. Zhang, J. Fu, T. Shirai, S. Kojima, and N. Ohta. 2000. Protective mechanisms against the intestinal nematode Strongyloides venezuelensis in Schistosoma japonicum-infected mice. Parasite Immunol.22:279-286.
    OpenUrlCrossRefPubMed
  72. 72.↵
    McLarnon, M., and P. Ma. 1981. Brain stem glioma complicated by Strongyloides stercoralis. Ann. Clin. Lab. Sci.11:546-549.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    McNeely, D. J., T. Inouye, P. Y. Tam, and S. D. Ripley. 1980. Acute respiratory failure due to strongyloidiasis in polymyositis. J. Rheumatol.7:745-750.
    OpenUrlPubMed
  74. 74.↵
    Morgan, J. S., W. Schaffner, and W. J. Stone. 1986. Opportunistic strongyloidiasis in renal transplant recipients. Transplantation42:518-524.
    OpenUrlPubMedWeb of Science
  75. 75.↵
    Morgello, S., F. M. Soifer, C. S. Lin, and D. E. Wolfe. 1993. Central nervous system Strongyloides stercoralis in acquired immunodeficiency syndrome: a report of two cases and review of the literature. Acta Neuropathol.86:285-288.
    OpenUrlCrossRefPubMed
  76. 76.↵
    Mori, S., T. Konishi, K. Matsuoka, M. Deguchi, M. Ohta, O. Mizuno, T. Ueno, T. Okinaka, Y. Nishimura, N. Ito, and T. Nakano. 1998. Strongyloidiasis associated with nephrotic syndrome. Intern. Med.37:606-610.
    OpenUrlPubMed
  77. 77.↵
    Morimoto, J., H. Kaneoka, Y. Sasatomi, Y. N. Sato, T. Murata, S. Ogahara, N. Sakata, S. Takebayashi, S. Naito, and T. Saito. 2002. Disseminated strongyloidiasis in nephrotic syndrome. Clin. Nephrol.57:398-401.
    OpenUrlPubMed
  78. 78.↵
    Nandy, A., M. Addy, P. Patra, and A. K. Bandyopashyay. 1995. Fulminating strongyloidiasis complicating Indian kala-azar. Trop. Geogr. Med.47:139-141.
    OpenUrlPubMed
  79. 79.↵
    Neefe, L. I., O. Pinilla, V. F. Garagusi, and H. Bauer. 1973. Disseminated strongyloidiasis with cerebral involvement. A complication of corticosteroid therapy. Am. J. Med.55:832-838.
    OpenUrlCrossRefPubMedWeb of Science
  80. 80.↵
    Neva, F. A. 1994. Intestinal nematodes of human beings, p. 123-128. In F. A. Neva (ed.), Basic clinical parasitology. Appleton & Lange, Norwalk, Conn.
  81. 81.↵
    Neva, F. A., J. O. Filho, A. A. Gam, R. Thompson, V. Freitas, A. Melo, and E. M. Carvalho. 1998. Interferon-γ and interleukin-4 responses in relation to serum IgE levels in persons infected with human T lymphotropic virus type I and Strongyloides stercoralis. J. Infect. Dis.178:1856-1859.
    OpenUrlCrossRefPubMedWeb of Science
  82. 82.↵
    Neva, F. A., A. A. Gam, C. Maxwell, and L. L. Pelletier. 2001. Skin test antigens for immediate hypersensitivity prepared from infective larvae of Strongyloides stercoralis. Am. J. Trop. Med. Hyg.65:567-572.
    OpenUrlAbstract
  83. 83.↵
    Newton, R. C., P. Limpuangthip, S. Greenberg, A. Gam, and F. A. Neva. 1992. Strongyloides stercoralis hyperinfection in a carrier of HTLV-1 virus with evidence of selective immunosuppression. Am. J. Med.92:202-208.
    OpenUrlCrossRefPubMedWeb of Science
  84. 84.↵
    Nomura, J., and K. Rekrut. 1996. Strongyloides stercoralis hyperinfection syndrome in a patient with AIDS: diagnosis by fluorescent microscopy. Clin. Infect. Dis.22:736.
    OpenUrlCrossRefPubMed
  85. 85.↵
    Nonaka, D., K. Takaki, M. Tanaka, M. Umeno, T. Takeda, M. Yoshida, Y. Haraguch, K. Okada, and Y. Sawai. 1998. Paralytic ileus due to strongyloidiasis: case report and review of the literature. Am. J. Trop. Med. Hyg.59:535-538.
    OpenUrlAbstract
  86. 86.↵
    Nucci, M., R. Portugal, W. Pulcheri, N. Spector, S. B. Ferreira, M. B. de Castro, R. Noe, and H. P. de Oliveira. 1995. Strongyloidiasis in patients with hematologic malignancies. Clin. Infect. Dis.21:675-677.
    OpenUrlCrossRefPubMedWeb of Science
  87. 87.↵
    Palau, L. A., and G. A. Pankey. 1997. Strongyloides hyperinfection in a renal transplant recipient receiving cyclosporine: possible Strongyloides stercoralis transmission by kidney transplant. Am. J. Trop. Med. Hyg.57:413-415.
    OpenUrlAbstract/FREE Full Text
  88. 88.↵
    Pawlowski, Z. S. 1989. Epidemiology, prevention and control, p. 233-249. In D. I. Grove (ed.), Strongyloidiasis: a major roundworm infection of man. Taylor & Francis, Philadelphia, Pa.
  89. 89.↵
    Pelletier, L. L. Jr., and T. Gabre-Kidan. 1985. Chronic strongyloidiasis in Vietnam veterans. Am. J. Med.78:139-140.
    OpenUrlCrossRefPubMedWeb of Science
  90. 90.↵
    Plumelle, Y., C. Gonin, A. Edouard, b. J. Bucher, L. Thomas, A. Brebion, and G. Panelatti. 1997. Effect of Strongyloides stercoralis infection and eosinophilia on age at onset and prognosis of adult T-cell leukemia. Am. J. Clin. Pathol.107:81-87.
    OpenUrlPubMed
  91. 91.↵
    Porto, A. F., F. A. Neva, H. Bittencourt, W. Lisboa, R. Thompson, L. Alcantara, and E. M. Carvalho. 2001. HTLV-1 decreases Th2 type of immune response in patients with strongyloidiasis. Parasite Immunol.23:503-507.
    OpenUrlCrossRefPubMedWeb of Science
  92. 92.↵
    Porto, A. F., J. Oliveira Filho, F. A. Neva, G. Orge, L. Alcantara, A. Gam, and E. M. Carvalho. 2001. Influence of human T-cell lymphocytotropic virus type 1 infection on serologic and skin tests for strongyloidiasis. Am. J. Trop. Med. Hyg.65:610-613.
    OpenUrlAbstract
  93. 93.↵
    Proctor, E. M., H. A. Muth, D. L. Proudfoot, A. B. Allen, R. Fisk, J. Isaac-Renton, and W. A. Black. 1987. Endemic institutional strongyloidiasis in British Columbia. Can. Med. Assoc. J.136:1173-1176.
    OpenUrlAbstract
  94. 94.↵
    Rivera, E., N. Maldonado, E. Velez-Garcia, A. J. Grillo, and G. Malaret. 1970. Hyperinfection syndrome with Strongyloides stercoralis. Ann. Intern. Med.72:199-204.
    OpenUrlCrossRefPubMed
  95. 95.↵
    Rogers, W. A. Jr., and B. Nelson. 1966. Strongyloidiasis and malignant lymphoma. “Opportunistic infection” by a nematode. JAMA195:685-687.
    OpenUrlCrossRefPubMed
  96. 96.↵
    Ron, I. G., S. Berger, M. J. Inbar, S. Chaitchik, and Y. Siegman-Igra. 1992. Strongyloides stercoralis hyperinfection in Israel—a case report. Isr. J. Med. Sci.28:736-738.
    OpenUrlPubMed
  97. 97.↵
    Ronan, S. G., R. L. Reddy, J. R. Manaligod, J. Alexander, and T. Fu. 1989. Disseminated strongyloidiasis presenting as purpura. J. Am. Acad. Dermatol.21:1123-1125.
    OpenUrlPubMed
  98. 98.↵
    Sanchez, P. R., A. P. Guzman, S. M. Guillen, R. I. Adell, A. M. Estruch, I. N. Gonzalo, and C. R. Olmos. 2001. Endemic strongyloidiasis on the Spanish Mediterranean coast. Q. J. Med.94:357-363.
    OpenUrlCrossRefPubMedWeb of Science
  99. 99.↵
    Sandlund, J. T., W. Kauffman, and P. M. Flynn. 1997. Strongyloides stercoralis infection mimicking relapse in a child with small noncleaved cell lymphoma. Am. J. Clin. Oncol.20:215-216.
    OpenUrlCrossRefPubMed
  100. 100.↵
    Sarangarajan, R., A. H. Belmonte, and V. Tchertkoff. 1997. Strongyloides stercoralis hyperinfection diagnosed by gastric cytology in an AIDS patient. AIDS11:394-396.
    OpenUrlPubMed
  101. 101.↵
    Sarubbi, F. A. 1987. Hyperinfection with Strongyloides during treatment of pemphigus vulgaris. Arch. Dermatol.123:864-865.
    OpenUrlCrossRefPubMedWeb of Science
  102. 102.↵
    Satoh, M., H. Toma, Y. Sato, M. Takara, Y. Shiroma, S. Kiyuna, and K. Hirayama. 2002. Reduced efficacy of treatment of strongyloidiasis in HTLV-1 carriers related to enhanced expression of IFN-γ and TGF-β1. Clin. Exp. Immunol.127:354-359.
    OpenUrlCrossRefPubMedWeb of Science
  103. 103.↵
    Satoh, M., H. Toma, K. Sugahara, K. Etoh, Y. Shiroma, S. Yiyuna, M. Takara, M. Matsuoka, K. Yamaguchi, K. Nakada, K. Fujita, S. Kojima, E. Hori, Y. Tanaka, S. Kamihira, Y. Sato, and T. Watanabe. 2002. Involvement of IL-2/IL-2R system activation by parasite antigen in polyclonal expansion of CD4+25+ HTLV-1-infected T-cells in human carriers of both HTLV-1 and S. stercoralis.Oncogene21:2466-2475.
    OpenUrlCrossRefPubMedWeb of Science
  104. 104.↵
    Savage, D., M. Foadi, C. Haworth, and A. Grant. 1994. Marked eosinophilia in an immunosuppressed patient with strongyloidiasis. J. Intern. Med.236:473-475.
    OpenUrlPubMed
  105. 105.↵
    Schad, G. A. 1986. Cyclosporine may eliminate the threat of overwhelming Strongyloides in immunosuppressed patients. J. Infect. Dis.153:178.
    OpenUrlCrossRefPubMedWeb of Science
  106. 106.↵
    Schad, G. A., L. M. Aikens, and G. Smith. 1989. Strongyloides stercoralis: is there a canonical migratory route through the host? J. Parasitol.75:740-749.
    OpenUrlCrossRefPubMed
  107. 107.↵
    Schaffel, R., M. Nucci, E. Carvalho, M. Braga, L. Almeida, R. Portugal, and W. Pulcheri. 2001. The value of an immunoenzymatic test (enzyme-linked immunosorbent assay) for the diagnosis of strongyloidiasis in patients immunosuppressed by hematologic malignancies. Am. J. Trop. Med. Hyg.65:346-350.
    OpenUrlAbstract
  108. 108.↵
    Scowden, E. B., W. Schaffner, and W. J. Stone. 1978. Overwhelming strongyloidiasis: an unappreciated opportunistic infection. Medicine (Baltimore)57:527-544.
    OpenUrlCrossRefPubMedWeb of Science
  109. 109.↵
    Sen, P., C. Gil, B. Estrellas, and J. R. Middleton. 1995. Corticosteroid-induced asthma: a manifestation of limited hyperinfection syndrome due to Strongyloides stercoralis. South. Med. J.88:923-927.
    OpenUrlCrossRefPubMedWeb of Science
  110. 110.↵
    Shelhamer, J. H., F. A. Neva, and D. R. Finn. 1982. Persistent strongyloidiasis in an immunodeficient patient. Am. J. Trop. Med. Hyg.31:746-751.
    OpenUrlAbstract/FREE Full Text
  111. 111.↵
    Siddiqui, A. A., and S. L. Berk. 2001. Diagnosis of Strongyloides stercoralis infection. Clin. Infect. Dis.33:1040-1047.
    OpenUrlCrossRefPubMedWeb of Science
  112. 112.↵
    Siddiqui, A. A., C. S. Stanley, P. J. Skelly, and S. L. Berk. 2000. A cDNA encoding a nuclear hormone receptor of the steroid/thyroid hormone-receptor superfamily from the human parasitic nematode Strongyloides stercoralis. Parasitol. Res.86:24-29.
    OpenUrlCrossRefPubMedWeb of Science
  113. 113.↵
    Smith, B., A. Verghese, C. Guiterrez, W. Dralle, and S. L. Berk. 1985. Pulmonary strongyloidiasis. Diagnosis by sputum Gram stain. Am. J. Med.79:663-666.
    OpenUrlCrossRefPubMedWeb of Science
  114. 114.↵
    Steiner, B., D. Riebold, D. Wolff, M. Freund, and E. C. Reisinger. 2002. Strongyloides stercoralis eggs in a urethral smear after bone marrow transplantation. Clin. Infect. Dis.34:1280-1281.
    OpenUrlCrossRefPubMedWeb of Science
  115. 115.↵
    Stey, C., J. Jost, and R. Luthy. 1990. Extraintestinal strongyloidiasis in the acquired immunodeficiency syndrome. Dtsch. Med. Wochenschr.115:1716-1719. (In German.)
    OpenUrlPubMed
  116. 116.↵
    Stone, W. J., and W. Schaffner. 1990. Strongyloides infections in transplant recipients. Semin. Respir. Infect.5:58-64.
    OpenUrlPubMed
  117. 117.↵
    Sullivan, T. J., and S. C. Hembree. 1970. Enhancement of the density of circulating microfilariae with diethylcarbamazine. Trans. R. Soc. Trop. Med. Hyg.64:787-788.
    OpenUrlCrossRefPubMed
  118. 118.↵
    Tabacof, J., O. Feher, A. Katz, S. D. Simon, and R. C. Gansl. 1991. Strongyloides hyperinfection in two patients with lymphoma, purulent meningitis, and sepsis. Cancer68:1821-1823.
    OpenUrlCrossRefPubMed
  119. 119.↵
    Takayanagui, O. M., M. M. Lofrano, M. B. Araugo, and L. Chimelli. 1995. Detection of Strongyloides stercoralis in the cerebrospinal fluid of a patient with acquired immunodeficiency syndrome. Neurology45:193-194.
    OpenUrlAbstract/FREE Full Text
  120. 120.↵
    Tanton, D. D., S. Durning, and S. Chambers. 2002. Pulmonary hyperinfection with Strongyloides stercoralis in an immunocompetent patient. J. Gen. Intern. Med.17:72-73.
    OpenUrl
  121. 121.↵
    Thomas, M. C., and S. A. Costello. 1998. Disseminated strongyloidiasis arising from a single dose of dexamethasone before stereotactic radiosurgery. Int. J. Clin. Pract.52:520-521.
    OpenUrlPubMed
  122. 122.↵
    Thompson, J. R., and R. Berger. 1991. Fatal adult respiratory distress syndrome following successful treatment of pulmonary strongyloidiasis. Chest99:772-774.
    OpenUrlCrossRefPubMedWeb of Science
  123. 123.↵
    Torres, J. R., R. Isturiz, J. Murillo, M. Guzman, and R. Contreras. 1993. Efficacy of ivermectin in the treatment of strongyloidiasis complicating AIDS. Clin. Infect. Dis.17:900-902.
    OpenUrlCrossRefPubMed
  124. 124.↵
    Tullis, T. C. 1970. Bronchial asthma associated with intestinal parasites. N. Engl. J. Med.282:370-372.
    OpenUrlCrossRefPubMedWeb of Science
  125. 125.↵
    Venizelos, P. C., M. Lopata, W. A. Bardawil, and J. T. Sharp. 1980. Respiratory failure due to Strongyloides stercoralis in a patient with a renal transplant. Chest78:104-106.
    OpenUrlCrossRefPubMed
  126. 126.↵
    Vishwanath, S., R. A. Baker, and B. J. Mansheim. 1982. Strongyloides infection and meningitis in an immunocompromised host. Am. J. Trop. Med. Hyg.31:857-858.
    OpenUrlAbstract/FREE Full Text
  127. 127.↵
    Wagenvoort, J. H., H. G. Houben, G. L. Boonstra, and J. Scherpbier. 1994. Pulmonary superinfection with Strongyloides stercoralis in an immunocompromised retired coal miner. Eur. J. Clin. Microbiol. Infect. Dis.13:518-519.
    OpenUrlCrossRefPubMed
  128. 128.↵
    Walzer, P. D., J. E. Milder, J. G. Banwell, G. Kilgore, M. Klein, and R. Parker. 1982. Epidemiologic features of Strongyloides stercoralis infection in an endemic area of the United States. Am. J. Trop. Med. Hyg.31:313-319.
    OpenUrlAbstract/FREE Full Text
  129. 129.↵
    Weller, I. V., P. Copland, and R. Gabriel. 1981. Strongyloides stercoralis infection in renal transplant recipients. Br. Med. J. (Clin. Res. Ed.)282:524.
    OpenUrlPubMed
  130. 130.↵
    West, B. C., and J. P. Wilson. 1980. Subconjunctival corticosteroid therapy complicated by hyperinfective strongyloidiasis. Am. J. Ophthalmol.89:854-857.
    OpenUrlPubMed
  131. 131.↵
    White, J. V., G. Garvey, and M. A. Hardy. 1982. Fatal strongyloidiasis after renal transplantation: a complication of immunosuppression. Am. Surg.48:39-41.
    OpenUrlPubMed
  132. 132.↵
    Wilkinson, R., and C. L. Leen. 1993. Chronic lymphocytic leukaemia and overt presentation of underlying Strongyloides stercoralis infection. J. Infect.27:99-100.
    OpenUrlCrossRefPubMed
  133. 133.↵
    Wong, T. Y., C. C. Szeto, F. F. Lai, C. K. Mak, and P. K. Li. 1998. Nephrotic syndrome in strongyloidiasis: remission after eradication with anthelmintic agents. Nephron79:333-336.
    OpenUrlCrossRefPubMedWeb of Science
  134. 134.↵
    World Health Organization. 1986. Acquired immunodeficiency syndrome (AIDS). WHO/CDC case definition for AIDS. Wkly. Epidemiol. Rec.61:69-73.
    OpenUrl
  135. 135.↵
    Wurtz, R., M. Mirot, G. Fronda, C. Peters, and F. Kocka. 1994. Short report: gastric infection by Strongyloides stercoralis. Am. J. Trop. Med. Hyg.51:339-340.
    OpenUrlAbstract/FREE Full Text
  136. 136.↵
    Yee, A., C. T. Boylen, T. Noguchi, E. C. Klatt, and O. P. Sharma. 1987. Fatal Strongyloides stercoralis infection in a patient receiving corticosteroids. West. J. Med.146:363-364.
    OpenUrlPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Strongyloides stercoralis in the Immunocompromised Population
Paul B. Keiser, Thomas B. Nutman
Clinical Microbiology Reviews Jan 2004, 17 (1) 208-217; DOI: 10.1128/CMR.17.1.208-217.2004

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Clinical Microbiology Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Strongyloides stercoralis in the Immunocompromised Population
(Your Name) has forwarded a page to you from Clinical Microbiology Reviews
(Your Name) thought you would be interested in this article in Clinical Microbiology Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Strongyloides stercoralis in the Immunocompromised Population
Paul B. Keiser, Thomas B. Nutman
Clinical Microbiology Reviews Jan 2004, 17 (1) 208-217; DOI: 10.1128/CMR.17.1.208-217.2004
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • SUMMARY
    • INTRODUCTION
    • LIFE CYCLE
    • EPIDEMIOLOGY
    • CLINICAL SYNDROMES
    • HYPERINFECTION SYNDROME
    • IMMUNOCOMPROMISED CONDITIONS ASSOCIATED WITH S. STERCORALIS
    • DIAGNOSIS OF S. STERCORALIS INFECTION IN THE IMMUNOCOMPROMISED PATIENT
    • TREATMENT OF S. STERCORALIS IN THE IMMUNOCOMPROMISED PATIENT
    • CONCLUSIONS
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Info & Metrics
  • PDF

KEYWORDS

Immunocompromised Host
Strongyloides stercoralis
Strongyloidiasis

Related Articles

Cited By...

About

  • About CMR
  • Editor in Chief
  • Editorial Board
  • Policies
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Ethics
  • Contact Us

Follow #ClinMicroRev

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0893-8512; Online ISSN: 1098-6618